PrecivityAD2 is a blood test that the FDA cleared on August 20, 2026 for adults aged 40 and older who show signs of cognitive impairment, making it the first Alzheimer's blood test authorized down to that age. For families dealing with younger-onset Alzheimer's — disease that starts before 65 — the lower age threshold is significant, but the test's accuracy numbers were built mostly on patients 50 and older, which leaves a real gap for the youngest group it now covers.
This matters because younger-onset Alzheimer's is already harder to diagnose: doctors are less likely to suspect it, and symptoms get mistaken for stress, depression, or menopause. A blood test that works well can shorten that delay. But knowing exactly what the test can and cannot tell a 42-year-old versus a 62-year-old is the difference between using it well and misreading what a result means.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What PrecivityAD2 Measures and What the FDA Actually Cleared
- How Accurate Is the Test — and What Does "Likely Positive" Mean?
- The Evidence Gap Between Ages 40 and 49
- What This Means for Families Facing Younger-Onset Symptoms
- Frequently Asked Questions
What PrecivityAD2 Measures and What the FDA Actually Cleared
PrecivityAD2, made by C2N Diagnostics, uses a single blood draw and high-resolution mass spectrometry to measure two markers: the plasma amyloid-beta 42/40 ratio and %p-tau217, a form of the tau protein linked to Alzheimer's brain changes. The two measurements combine into a proprietary Amyloid Probability Score 2, which the lab reports as negative, positive, or an intermediate "likely positive" result, according to NeurologyLive's coverage of the clearance. The FDA's clearance is narrower than "a test for Alzheimer's." It applies only to adults 40 and older who already have signs or symptoms of cognitive impairment, and the clearance explicitly states that PrecivityAD2 must be used alongside a clinical assessment — it is not a stand-alone diagnostic and not a tool for screening people with no symptoms, according to Practical Neurology.
That distinction matters for younger-onset families: a positive result is one input a neurologist weighs, not a diagnosis delivered by mail. Alzheimer's Association president and CEO Joanne Pike said extending the clearance to age 40 recognizes that younger-onset Alzheimer's affects many families and can help more of them get clarity and start care planning sooner. The Association noted PrecivityAD2 is now the third FDA-cleared blood-based biomarker test for Alzheimer's, part of a fast-moving shift away from spinal taps and PET scans as the only confirmatory options.
How Accurate Is the Test — and What Does "Likely Positive" Mean?
In the validation study behind the 2026 clearance, which included 1,142 participants and used amyloid PET scans or spinal fluid testing as the reference standard, a positive PrecivityAD2 result carried a 97.6% positive predictive value, and a negative result carried a 93.1% negative predictive value, according to C2N Diagnostics' announcement. In plain terms, a clear positive or clear negative result tracked closely with what a PET scan or spinal tap would have shown. The intermediate "likely positive" category is where that confidence drops.
It showed up in 17.3% of participants in the same study, and it carried only a 77.3% positive predictive value — meaning roughly one in five patients lands in a zone where the blood test cannot settle the question on its own. For those patients, the same source confirms the result points toward further workup, such as a PET scan or spinal fluid test, rather than a usable answer. For a younger-onset family, that intermediate category is worth asking about directly before testing. A clean positive or negative result is close to decisive; a "likely positive" means budgeting for a second, more invasive test regardless of what the blood draw shows.
The Evidence Gap Between Ages 40 and 49
PrecivityAD2's age range has moved twice in roughly a year, and each move outran the data behind it. The test was first validated and marketed for ages 60 and older, then in August 2025 C2N lowered the floor to 50 and older, citing a JAMA study of more than 1,200 patients that found over 90% accuracy against spinal fluid or PET results at a single preset cutoff. The August 2026 clearance pushed the floor down again, to 40, but age-specific subgroup data in public reporting extends only down to roughly ages 50 to 55. No peer-reviewed or company-published validation data specific to the 40-to-49 age band has surfaced in coverage of the clearance, according to NeurologyLive.
That means the 97.6% and 93.1% figures families in their 40s would naturally reference were generated mostly in older patients, not people their own age. Real-world ordering guidance has already lagged behind the label. After the 2025 update to age 50, some hospital lab catalogs continued to list PrecivityAD2 as intended only for patients 50 and older and "not intended for patients younger than 50," as shown in MaineGeneral Health's test catalog. A family in their 40s asking a local hospital lab for the test may find the lab's own paperwork has not caught up to the 2026 clearance.
What This Means for Families Facing Younger-Onset Symptoms
The practical reality in late 2026 is a short transition window. At the time of the clearance announcement, the FDA-cleared version of PrecivityAD2 was expected to reach the market later in 2026, while the existing CLIA-validated laboratory version remained available in the interim through C2N's own clinical lab, according to HealthDay.
A family asking about the test now may be offered the lab version rather than the newly cleared one, and it is worth asking which version a clinician is ordering. Because the clearance requires symptoms and a clinical assessment, the test is built for someone already showing memory or thinking changes, not a healthy 42-year-old who wants reassurance. A primary care doctor or neurologist should be the one ordering it and interpreting the result alongside a cognitive exam, not a result read in isolation.
- Confirm the test is being ordered for a person with actual symptoms, not as a screening tool — the clearance does not cover screening.
- Ask which version is being used: the newly FDA-cleared test or C2N's existing lab-based version.
- Ask in advance what happens if the result comes back "likely positive," since that result alone will not settle the question.
- If you are in your 40s, ask the ordering clinician whether they are aware the supporting accuracy data was gathered mostly in patients 50 and older.
- Treat a positive or negative result as one piece of a larger evaluation that should include a clinical assessment, not a final answer by itself.
Frequently Asked Questions
Does a negative PrecivityAD2 result rule out Alzheimer's?
A negative result carried a 93.1% negative predictive value in the validation study behind the 2026 clearance, which is strong but not absolute, and the clearance still requires it to be interpreted alongside a clinical assessment rather than used on its own.
Can someone in their 40s with no symptoms get PrecivityAD2 as a screening test?
No. The clearance covers adults 40 and older who already have signs or symptoms of cognitive impairment, and it explicitly excludes use as a population screening tool.
Why would a lab still say the test is only for patients 50 and older?
Lab test catalogs can lag behind a new FDA label; MaineGeneral Health's catalog still listed the 50-and-older restriction after the 2025 update, showing real-world ordering guidance does not always update as fast as the clearance itself.
You Might Also Like
- The Third FDA-Cleared Alzheimer’s Blood Biomarker Test in 2026: Accuracy, Limits, and Evidence Gaps for Younger-Onset Alzheimer’s Families
- PrecivityAD2 as an Adjunct to a 2026 Alzheimer’s Assessment: Accuracy, Limits, and Evidence Gaps for Younger-Onset Alzheimer’s Families
- FDA’s 2026 PrecivityAD2 Alzheimer’s Blood Test Clearance: Accuracy, Limits, and Evidence Gaps for Younger-Onset Alzheimer’s Families
